Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.96EUR
18 May 2018
Change (% chg)

€0.00 (+0.17%)
Prev Close
€2.96
Open
€3.00
Day's High
€3.02
Day's Low
€2.94
Volume
27,744
Avg. Vol
98,095
52-wk High
€3.79
52-wk Low
€2.40

Latest Key Developments (Source: Significant Developments)

Transgene Q1 Operating Revenue Stable At 1.8 Million Euros
Thursday, 26 Apr 2018 

April 26 (Reuters) - Transgene SA ::TRANSGENE: €35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018.CLINICAL TRIALS NOW ON-GOING WITH 5 IMMUNO-THERAPEUTICS.CLINICAL READOUTS EXPECTED FOR EACH OF OUR 5 PRODUCTS IN 2018.Q1 OPERATING REVENUE EUR 1.8 MILLION VERSUS EUR 1.9 MILLION YEAR AGO.TRANSGENE EXPECTS ITS CASH BURN FOR 2018 TO BE COMPARABLE TO 2017.TRANSGENE CONFIRMS THAT IT EXPECTS READOUTS IN 2018 FOR EACH OF ITS 5 PRODUCTS IN CLINICAL DEVELOPMENT.  Full Article

Transgene To Announce Major Clinical Results In 2018
Wednesday, 21 Mar 2018 

March 21 (Reuters) - TRANSGENE SA ::TRANSGENE TO ANNOUNCE MAJOR CLINICAL RESULTS IN 2018 AND ACHIEVE PROMISING PROGRESS ON ITS NEW ONCOLYTIC VIRUSES.‍ALL CLINICAL PROGRAMS MADE PROGRESS​.‍CASH BURN IN 2017 WELL CONTROLLED AT EUR 28.1 MILLION​.LOOK AT 2018 WITH CONFIDENCE.CLINICAL RESULTS EXPECTED IN 2018 ON FIVE PRODUCTS.CASH AVAILABLE AT YEAR-END 2017: €41.4 MILLION, COMPARED TO €56.2 MILLION AT THE END OF 2016.NET LOSS OF €32.2 MILLION IN 2017, COMPARED TO A LOSS OF €25.2 MILLION IN 2016.EXPECTS ITS CASH BURN FOR 2018 TO BE COMPARABLE TO 2017.HAS THE FINANCIAL RESOURCES TO EXECUTE ITS STRATEGY THROUGH MID-2019..  Full Article

Transgene Collaborates with BioInvent To Treat Solid Tumors
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - TRANSGENE SA ::BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS.‍COLLABORATION'S RESEARCH AND DEVELOPMENT COSTS, AS WELL AS REVENUES AND ROYALTIES, WILL BE SHARED 50:50​.WILL CONTRIBUTE BOTH ITS OV DESIGN AND ENGINEERING EXPERTISE AS WELL AS ITS PROPRIETARY ENGINEERED VACCINIA VIRUS.  Full Article

Transgene successfully raises 14.4 million euros
Friday, 10 Nov 2017 

Nov 10 (Reuters) - TRANSGENE SA ::TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS.‍TRANSACTION WAS OVERSUBSCRIBED, AT EUR 2.55 PER SHARE​.‍NEW SHARES WILL HAVE A PAR VALUE OF ONE EURO EACH​.‍NEW SHARES CARRY DIVIDEND RIGHTS AS FROM THEIR ISSUE DATE​.‍NEW SHARES' ADMISSION TO TRADING EXPECTED TO OCCUR ON NOV 14, 2017 ON EURONEXT IN PARIS​.  Full Article

Transgene launches capital increase by accelerated book-build offering
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - TRANSGENE SA ::TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING.‍CAPITAL INCREASE WITHOUT PREFERENTIAL SUBSCRIPTION RIGHTS THROUGH ISSUANCE OF UP TO 5,643,199 ORDINARY SHARES​.‍TO ISSUE OF UP TO 5,643,199 ORDINARY SHARES OF COMPANY, REPRESENTING APPROXIMATELY 10% OF EXISTING ISSUED SHARE CAPITAL​.‍GROSS PROCEEDS FROM TRANSACTION ARE EXPECTED TO BE APPROXIMATELY EUR 14 MILLION​.‍FUNDS RAISED WILL BE USED TO PURSUE CLINICAL AND PRECLINICAL DEVELOPMENT OF TRANSGENE'S INNOVATIVE IMMUNOTHERAPIES​.‍ADMISSION TO TRADING OF NEW SHARES EXPECTED TO OCCUR ON NOVEMBER 14, 2017 ON EURONEXT IN PARIS​.  Full Article

Transgene Q3 operating revenue drops to 1.4‍​ million euros
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - TRANSGENE SA ::Q3 OPERATING REVENUE EUR 1.4‍​ MILLION VERSUS EUR 1.5 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AT SEPT. 30 EUR 40.0‍​ MILLION VERSUS EUR 56.2 MILLION AT DEC. 31, 2016.CONFIRMS OUTLOOK OF CASH BURN ABOUT 30 MILLION EUROS‍​ IN FY 2017.  Full Article

Transgene says first patient treated in a phase 1B/2 trial of TG4001
Tuesday, 19 Sep 2017 

Sept 19 (Reuters) - TRANSGENE SA ::TRANSGENE: FIRST PATIENT TREATED IN A PHASE 1B/2 TRIAL OF TG4001 IN COMBINATION WITH AVELUMAB IN HPV-POSITIVE CANCERS.‍FIRST RESULTS EXPECTED IN 2018​.  Full Article

Transgene H1 operating loss widens at 16.1 million euros
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - TRANSGENE SA : :TRANSGENE: FIRST HALF-YEAR 2017 IN LINE WITH OUR OBJECTIVES: ALL CLINICAL PROGRAMS PROGRESSING AND NEW COLLABORATION AGREEMENTS SIGNED.‍CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2017: EUR 43.9 MILLION, FINANCIAL VISIBILITY CONFIRMED TO END OF 2018​.H1 OPERATING REVENUES EUR ‍​3.9 MILLION VERSUS EUR 5.3 MILLION YEAR AGO.H1 COMPREHENSIVE NET LOSS EUR 18.3 MILLION VERSUS LOSS OF EUR 12.2 MILLION YEAR AGO.IS ‍WELL PLACED TO PROGRESS ITS PROGRAMS THROUGH TO END OF 2018​.H1 COMPREHENSIVE NET LOSS EUR 18.3‍​ MILLION VERSUS LOSS OF EUR 12.2 MILLION YEAR AGO.EXPECTS 2017 CASH BURN TO BE AROUND EUR 30 MILLION.H1 OPERATING LOSS EUR ‍​16.1 MILLION VERSUS LOSS OF EUR 10.7 MILLION YEAR AGO.  Full Article

Transgene says U.S. FDA grants IND clearance to Phase 2 trial of TG4010 in combination with Opdivo
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Transgene SA ::Receives FDA IND approval to begin a clinical trial with TG4010 + Nivolumab + Chemotherapy in the first-line treatment of Lung Cancer (NSCLC).‍Phase 2 clinical trial is in collaboration with Bristol-Myers Squibb​.First patient expected to be enrolled at end of 2017.  Full Article

Transgene presents results of phase 1 part of METROmaJX trial
Thursday, 7 Sep 2017 

Sept 7 (Reuters) - TRANSGENE SA ::ANNOUNCES RESULTS OF PHASE 1 PART OF METROMAJX TRIAL.PHASE 2 PART OF THE TRIAL IS CURRENTLY ENROLLING PATIENTS.PHASE 1 TRIAL RESULTS SHOWED THAT REGIMEN ASSOCIATING INTRAVENOUS INFUSION OF PEXA-VEC (JX-594) WITH LOW-DOSE CYCLOPHOSPHAMIDE WAS WELL-TOLERATED WITH NO DOSE LIMITING TOXICITY IN PATIENTS WITH SOLID TUMORS.  Full Article

BRIEF-Transgene Q1 Operating Revenue Stable At 1.8 Million Euros

* TRANSGENE: €35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018